Developing treatments to help protect people with food allergies

Our portfolio of development programs targets the most prevalent food allergies, starting with peanut, using our characterized oral desensitization immunotherapy (CODIT™) approach.

We are currently conducting PALISADE, our Phase 3 pivotal trial for AR101 for the treatment of peanut allergy.  We plan to follow our AR101 program with additional programs for other food allergies.

Program
  • PRE-IND
  • PHASE 1/2*
  • PHASE 3
  • APPROVED
phase
  • PRE-IND
  • PHASE 1/2*
  • PHASE 3
  • APPROVED
PH 3

Peanut allergy is one of the most common food allergies and appears to be on the rise in children. Reactions from even a trace amount of the allergen can be severe and include potentially fatal anaphylaxis. Peanut allergies tend to be life long, with only approximately 20 percent of peanut-allergic children eventually outgrowing the allergy.

  • PRE-IND
  • PHASE 1/2*
  • PHASE 3
  • APPROVED
PRE-IND

We are planning to initiate a second development program, targeting egg allergy.

  • PRE-IND
  • PHASE 1/2*
  • PHASE 3
  • APPROVED
PRE-IND

We are evaluating other opportunities to initiate a third development program.

*Because (1) our treatment product candidates are based on foods that have not shown toxicology issues except in their functions as allergens, we have not been required to and at this time do not anticipate conducting Phase 1 clinical trials.